Esperion reports Q3 EPS (43c), consensus (6c)

Reports Q3 revenue $87.3M, consensus $77.8M. “Our Q3 performance reflects consistently strong execution across our commercial, clinical, and global expansion strategies. We delivered robust year-over-year revenue growth, driven by increased U.S. prescription volume and expanded payer coverage, now reaching over 90% of commercial lives and more than 80% of Medicare lives. The recent settlement agreement with Dr. Reddy’s, along with earlier settlements with three other ANDA filers, supports our ability to build and maintain our market leadership for many years to come. We’re seeing strong momentum in healthcare practitioner engagement and patient access, driven by innovative consumer campaigns and a strategic focus on statin intolerance. We’re building on this success through targeted investments that expand our commercial momentum,” stated CEO Sheldon Koenig. “The inclusion of bempedoic acid as a Class I, Level A recommendation in the 2025 ESC/EAS guidelines marks a pivotal moment in cardiovascular risk management. We believe this recognition will be reflected similarly in the upcoming U.S. guidelines expected in Q1 2026. In anticipation of this and our extended patent runway, throughout Q3 we invested in enhanced payer access, expanded sales and marketing initiatives, and patient access programs to ensure that we are leveraging these advantages to drive revenue growth and build a blockbuster franchise.”